428 related articles for article (PubMed ID: 18602920)
21. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
22. [Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line].
Wang LH; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):449-52. PubMed ID: 16383232
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.
Juurikivi A; Sandler C; Lindstedt KA; Kovanen PT; Juutilainen T; Leskinen MJ; Mäki T; Eklund KK
Ann Rheum Dis; 2005 Aug; 64(8):1126-31. PubMed ID: 16014680
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
Guida T; Anaganti S; Provitera L; Gedrich R; Sullivan E; Wilhelm SM; Santoro M; Carlomagno F
Clin Cancer Res; 2007 Jun; 13(11):3363-9. PubMed ID: 17545544
[TBL] [Abstract][Full Text] [Related]
25. TNF/LTalpha double knockout mice display abnormal inflammatory and regenerative responses to acute and chronic liver injury.
Knight B; Yeoh GC
Cell Tissue Res; 2005 Jan; 319(1):61-70. PubMed ID: 15592751
[TBL] [Abstract][Full Text] [Related]
26. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
Uziel O; Fenig E; Nordenberg J; Beery E; Reshef H; Sandbank J; Birenbaum M; Bakhanashvili M; Yerushalmi R; Luria D; Lahav M
Br J Cancer; 2005 May; 92(10):1881-91. PubMed ID: 15870711
[TBL] [Abstract][Full Text] [Related]
27. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.
Gross DJ; Munter G; Bitan M; Siegal T; Gabizon A; Weitzen R; Merimsky O; Ackerstein A; Salmon A; Sella A; Slavin S;
Endocr Relat Cancer; 2006 Jun; 13(2):535-40. PubMed ID: 16728580
[TBL] [Abstract][Full Text] [Related]
28. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Taylor JR; Brownlow N; Domin J; Dibb NJ
Oncogene; 2006 Jan; 25(1):147-51. PubMed ID: 16170366
[TBL] [Abstract][Full Text] [Related]
29. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
[TBL] [Abstract][Full Text] [Related]
30. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.
Yasuda A; Sawai H; Takahashi H; Ochi N; Matsuo Y; Funahashi H; Sato M; Okada Y; Takeyama H; Manabe T
Mol Cancer; 2006 Oct; 5():46. PubMed ID: 17044945
[TBL] [Abstract][Full Text] [Related]
31. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Bauer S; Duensing A; Demetri GD; Fletcher JA
Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.
Eckel F; von Delius S; Mayr M; Dobritz M; Fend F; Hosius C; Schleyer E; Schulte-Frohlinde E; Schmid RM; Lersch C
Oncology; 2005; 69(5):363-71. PubMed ID: 16319507
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines.
Kawamoto T; Akisue T; Marui T; Nakatani T; Hitora T; Fujita I; Kurosaka M; Yamamoto T
Anticancer Res; 2004; 24(5A):2675-9. PubMed ID: 15517872
[TBL] [Abstract][Full Text] [Related]
34. Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate.
Wang CH; Anderson N; Li SH; Szmitko PE; Cherng WJ; Fedak PW; Fazel S; Li RK; Yau TM; Weisel RD; Stanford WL; Verma S
Circ Res; 2006 Sep; 99(6):617-25. PubMed ID: 16931795
[TBL] [Abstract][Full Text] [Related]
35. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
Holtkamp N; Okuducu AF; Mucha J; Afanasieva A; Hartmann C; Atallah I; Estevez-Schwarz L; Mawrin C; Friedrich RE; Mautner VF; von Deimling A
Carcinogenesis; 2006 Mar; 27(3):664-71. PubMed ID: 16357008
[TBL] [Abstract][Full Text] [Related]
36. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
Hotfilder M; Lanvers C; Jürgens H; Boos J; Vormoor J
Cancer Chemother Pharmacol; 2002 Aug; 50(2):167-9. PubMed ID: 12172985
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate (IM)-induced growth inhibition is associated with production of spliced osteocalcin-mRNA in cell lines.
Wihlidal P; Karlic H; Pfeilstöcker M; Klaushofer K; Varga F
Leuk Res; 2008 Mar; 32(3):437-43. PubMed ID: 17822760
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat.
Nurmio M; Toppari J; Zaman F; Andersson AM; Paranko J; Söder O; Jahnukainen K
Int J Androl; 2007 Aug; 30(4):366-76; discussion 376. PubMed ID: 17705809
[TBL] [Abstract][Full Text] [Related]
39. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis.
Leipner C; Grün K; Müller A; Buchdunger E; Borsi L; Kosmehl H; Berndt A; Janik T; Uecker A; Kiehntopf M; Böhmer FD
Cardiovasc Res; 2008 Jul; 79(1):118-26. PubMed ID: 18326555
[TBL] [Abstract][Full Text] [Related]
40. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
Yokoyama T; Miyazawa K; Yoshida T; Ohyashiki K
Int J Oncol; 2005 Jan; 26(1):33-40. PubMed ID: 15586222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]